HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Sept. 22, 2015 (HealthDay News) -- As monotherapy, leukotriene-receptor antagonists (LTRAs) improve asthma control versus placebo, according to a review and meta-analysis published online Sept. 22 in the Annals of Internal Medicine.
Michael Miligkos, M.D., from the University of Thessaly School of Medicine in Larissa, Greece, and colleagues conducted a systematic review and meta-analysis to determine the benefits and harms of LTRAs as monotherapy or combined with inhaled corticosteroids compared with placebo for adults and adolescents with asthma. Fifty trials met the eligibility criteria for inclusion.
The researchers found that LTRAs reduced the risk of an exacerbation in random-effects meta-analyses of six trials of LTRA monotherapy (summary risk ratio, 0.60; 95 percent confidence interval, 0.44 to 0.81). The summary relative risk for exacerbation was 0.80 (95 percent confidence interval, 0.60 to 1.07) in four trials of LTRAs as add-on therapy to inhaled corticosteroids. Forced expiratory volume in one second (FEV1) was increased with LTRAs as monotherapy or add-on therapy to inhaled corticosteroids; the FEV1 percentage of predicted values was only improved in LTRA monotherapy trials. Similar adverse events rates were seen for the intervention and comparator groups.
"Leukotriene-receptor antagonists as monotherapy improved asthma control compared with placebo, but which patients are most likely to respond to treatment with LTRAs remains unclear," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 31, 2022